Topical Magnesium Orotate Lipogel in Kidney Transplant Recipients with Persistent Hypomagnesemia: Formulation Development and Pilot Clinical Study
Nutrients · 21.08.2026 · 18 (16) · 2740
DOI: 10.3390/nu18162740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 21.08.2026. Verfasst von Corina Moisa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania. Hauptthemen laut MEDLINE: Kidney Transplantation, Magnesium, Orotic Acid, Magnesium Deficiency. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oradea.
Abstract (Originalsprache)
Background
In solid-organ transplant recipients, hypomagnesemia is a frequent and persistent complication, predominantly related to long-term use of calcineurin inhibitors. Oral magnesium supplementation is often ineffective due to poor adherence, gastrointestinal adverse effects, and high treatment costs.
Objectives
This pilot study aimed to (i) develop a topical magnesium formulation for use in renal transplant recipients with persistent hypomagnesemia; (ii) evaluate the influence of formulation excipients on magnesium release from pharmaceutical preparations; and (iii) preliminarily assess the clinical outcomes, functional parameters, patient satisfaction, and tolerability associated with topical magnesium lipogel use in renal transplant recipients with persistent hypomagnesemia. Materials and Methods: Three lipogel formulations containing magnesium orotate, citrate, or sulfate were prepared and characterized in terms of organoleptic properties, pH, colloidal stability, and rheological behavior. In vitro magnesium release was evaluated using Franz diffusion cells. The formulation demonstrating the most favorable release profile, magnesium orotate lipogel, was administered twice daily for two months to 21 renal transplant recipients with persistent hypomagnesemia who had shown inadequate response, intolerance, or non-adherence to oral magnesium supplementation. Laboratory parameters were assessed at baseline and after treatment. Patient satisfaction was evaluated using the Lübeck questionnaire, while physical activity and exercise capacity were assessed using the International Physical Activity Questionnaire (IPAQ) and metabolic equivalent task (MET) calculations.
Results
Franz cell studies demonstrated superior magnesium release from the magnesium orotate lipogel compared with the other formulations. After two months, serum magnesium levels were higher than baseline (1.554 ± 0.124 vs. 1.448 ± 0.111 mg/dL, p < 0.001), although they remained below the normal reference range. No significant changes were observed in eGFR or hsCRP. Moderate-intensity physical activity increased significantly (310.475 ± 92.505 vs. 279.286 ± 89.907 MET-min/week, p < 0.001), while vigorous-intensity activity did not change significantly. No relevant adverse effects were reported. Patient satisfaction was high across all evaluated domains, including practicability (86.6%), efficacy (96.4%), tolerability (97.1%), and trust in medical professionals (97.6%).
Conclusions
In this pilot study, topical magnesium orotate lipogel was well tolerated and accepted by renal transplant recipients with persistent hypomagnesemia. Serum magnesium levels and moderate physical activity improved over the two-month observation period, although magnesium levels remained below the normal range. These preliminary findings warrant confirmation in larger, randomized, placebo-controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania.
- Doctoral School of Biomedical Sciences, University of Oradea, 1 Universitătii Street, 410073 Oradea, Romania.
- Faculty of Dentistry, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Victor Babeș Street 8, 400347 Cluj-Napoca, Romania.
ORCID-Profile: Ioana Adela Rațiu, Octavia Gligor, Laura Grațiela Vicaș, Csaba Nagy, Mariana Ganea
Förderung
- University of Oradea
Zitieren
APA
Moisa, C., Bănică, F., Rațiu, I. A., Gligor, O., Vicaș, L. G., Rațiu, C. A., Ganea, M. F., Nagy, C., Ratiu, A., Hagi Islai, E., & Ganea, M. (2026). Topical Magnesium Orotate Lipogel in Kidney Transplant Recipients with Persistent Hypomagnesemia: Formulation Development and Pilot Clinical Study. Nutrients, 18(16), 2740. https://doi.org/10.3390/nu18162740
Vancouver
Moisa C, Bănică F, Rațiu IA, Gligor O, Vicaș LG, Rațiu CA, et al. Topical Magnesium Orotate Lipogel in Kidney Transplant Recipients with Persistent Hypomagnesemia: Formulation Development and Pilot Clinical Study. Nutrients. 2026;18(16):2740. doi:10.3390/nu18162740
BibTeX
@article{Moisa2026,
author = {Moisa, Corina and Bănică, Florin and Rațiu, Ioana Adela and Gligor, Octavia and Vicaș, Laura Grațiela and Rațiu, Cristian Adrian and Ganea, Mădălin Florin and Nagy, Csaba and Ratiu, Anamaria and Hagi Islai, Edy and Ganea, Mariana},
title = {Topical Magnesium Orotate Lipogel in Kidney Transplant Recipients with Persistent Hypomagnesemia: Formulation Development and Pilot Clinical Study},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {16},
pages = {2740},
doi = {10.3390/nu18162740}
}
EUVIMED